Heat map of outcomes used in PMR RCTs
 |
|
Overall, clinical and laboratory components were mainly used as outcomes and treatment targets. Assessment of clinical items was part of the study outcomes in all RCTs, in terms of the evaluation of either remission, relapse or resolution of specific signs and symptoms. Primary and secondary endpoints are expressed with numbers ‘1’ and ‘2’ inserted as exponential values in each outcome.
ACTH: adrenocorticotropic hormone; AE, adverse events; GC: glucocorticoids; IL-6: interleukin 6; Lab: laboratory component; MS: morning stiffness; N: number of relapses; PMR-AS: PMR activity score; PROs: patient reported outcomes; TNF-a: tumor necrosis factor alpha.
Safety of treatment was summarized by extracting the data related to AEs bassessed through DEXA.
Shading: AEs reported without being considered as a treatment target.
Heat map of outcomes used in PMR RCTs
|
|
Overall, clinical and laboratory components were mainly used as outcomes and treatment targets. Assessment of clinical items was part of the study outcomes in all RCTs, in terms of the evaluation of either remission, relapse or resolution of specific signs and symptoms. Primary and secondary endpoints are expressed with numbers ‘1’ and ‘2’ inserted as exponential values in each outcome.
ACTH: adrenocorticotropic hormone; AE, adverse events; GC: glucocorticoids; IL-6: interleukin 6; Lab: laboratory component; MS: morning stiffness; N: number of relapses; PMR-AS: PMR activity score; PROs: patient reported outcomes; TNF-a: tumor necrosis factor alpha.
Safety of treatment was summarized by extracting the data related to AEs bassessed through DEXA.
Shading: AEs reported without being considered as a treatment target.
